-
The most commonly prescribed statins have a low incidence of rhabdomyolysis, according to the results a new study of more than 250,000 patients.
-
Increased hospitalizations for abnormal bleeding were found in new users of selective serotonin reuptake inhibitor (SSRI) antidepressants, with more risk associated with SSRIs containing greater degrees of serotonin reuptake inhibition.
-
Examining data from a 20-year time period, correlations were sought between antisecretory drug therapy and cumulative incidence of dysplasia. Incidence of dysplasia was significantly lower in patients who had received proton pump inhibitor therapy vs no therapy or H2-receptor antagonists.
-
Although chronic oral antiarrhythmic prophylaxis and catheter ablation both enjoy great success for preventing recurrences of atrial fibrillation (AF), some patients are not appropriate candidates for either method, especially patients with infrequent recurrences of AF.
-
Statins lower the levels of c-reactive protein (CRP) as well as the levels of LDL cholesterol (LDL-C). Whether lowering the CRP affects the clinical outcomes of statin therapy has not previously been investigated.
-
The addition of antiplatelet therapy to reduced intensity anticoagulation in atrial fibrillation patients reduces death and embolic events without increasing bleeding.
-
Pravastatin is the statin with the least interactions with cytochrome P450-(CYP) 3A4 inhibitors.
-
A new nonbenzodiazepine hypnotic has been approved by the FDA for the treatment of insomnia.
-
The most commonly prescribed statins have a low incidence of rhabdomyolysis, according to the results a new study of more than 250,000 patients.
-
Pregabalin has been approved for the management of neuropathic pain. It is the second drug to be approved for the treatment of painful diabetic neuropathy (after duloxetine) and the first drug to be approved for both diabetic neuropathy and postherpetic neuralgia.
